Powered by

Dexcom and Verily Amend Collaboration and License Agreement

Nov 20, 2018 - Business Wire

DexCom , Inc. ( NASDAQ:DXCM ), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, announced an amendment to the Collaboration and License Agreement surrounding the ongoing development efforts between the companies. The revised terms are intended to reinforce the companies' mutual product development goals, while expanding options for future collaborations. The agreement also accelerates Dexcom's efforts to advance into the Type 2 diabetes space and improves its fut...